Cargando…

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

BACKGROUND: Insulin therapy in type 2 diabetes may increase mortality and cancer incidence, but the impact of different types of basal insulins on these endpoints is unclear. Compared to the traditional NPH insulin, the newer, longer-acting insulin analogues detemir and glargine have shown benefits...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strandberg, Arto Y., Hoti, Fabian J., Strandberg, Timo E., Christopher, Solomon, Haukka, Jari, Korhonen, Pasi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4816506/ https://www.ncbi.nlm.nih.gov/pubmed/27031113 http://dx.doi.org/10.1371/journal.pone.0151910

Ejemplares similares

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
por: Porcellati, Francesca, et al.
Publicado: (2011)

Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
por: Johansen, Odd Erik, et al.
Publicado: (2009)

Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study†
por: Haukka, Jari, et al.
Publicado: (2013)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
por: Poon, Kitty, et al.
Publicado: (2010)

Comparison of Insulin Detemir and Insulin Glargine for Hospitalized Patients on a Basal-Bolus Protocol
por: Davis, Sondra, et al.
Publicado: (2017)

Comparison of the Efficacy and Safety of Insulin Glargine and Insulin Detemir with NPH Insulin in Children and Adolescents with Type 1 Diabetes Mellitus Receiving Intensive Insulin Therapy
por: Dündar, Bumin Nuri, et al.
Publicado: (2009)

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
por: Lucidi, Paola, et al.
Publicado: (2011)

Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin
por: Zafar, Mohammad Ishraq, et al.
Publicado: (2014)

All-Cause and Cardiovascular Mortality Among Insulin-Naïve People With Type 2 Diabetes Treated With Insulin Detemir or Glargine: A Cohort Study in the UK
por: Husemoen, Lise Lotte Nystrup, et al.
Publicado: (2021)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe, Shinya, et al.
Publicado: (2011)

Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
por: Rys, Przemyslaw, et al.
Publicado: (2015)

Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin
por: Lim, Soo, et al.
Publicado: (2014)

Insulin Detemir Versus Insulin Glargine in the Hospital: Do Hypoglycemia Rates Differ?
por: Crisher, Michelle A., et al.
Publicado: (2019)

Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany
por: Pscherer, Stefan, et al.
Publicado: (2010)

Insulin Detemir Is Transported From Blood to Cerebrospinal Fluid and Has Prolonged Central Anorectic Action Relative to NPH Insulin
por: Begg, Denovan P., et al.
Publicado: (2015)

Cost-Effectiveness of Insulin Glargine and Insulin Detemir in the Basal Regimen for Naïve Insulin Patients with Type 2 Diabetes Mellitus (T2DM) in Malaysia
por: Shafie, Asrul Akmal, et al.
Publicado: (2020)

Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
por: Stürmer, Til, et al.
Publicado: (2013)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
por: Esposito, Katherine, et al.
Publicado: (2012)

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study
por: Sharplin, Peter, et al.
Publicado: (2009)

Comparison of treatment with insulin detemir and NPH in women with gestational diabetes mellitus: glycemic control and pregnancy outcomes. A retrospective study
por: Kazakou, Paraskevi, et al.
Publicado: (2023)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
por: Kusunoki, Yoshiki, et al.
Publicado: (2013)

Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy
por: Lepercq, Jacques, et al.
Publicado: (2012)

A 26-week, randomized trial of insulin detemir versus NPH insulin in children and adolescents with type 2 diabetes (iDEAt2)
por: Wheeler, Mark D., et al.
Publicado: (2018)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
por: Asias, Bernadette D., et al.
Publicado: (2015)

Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review
por: Hagenmeyer, Ernst-Günther, et al.
Publicado: (2011)

Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain
por: Delgado, E
Publicado: (2012)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

Maternal Efficacy and Safety Outcomes in a Randomized, Controlled Trial Comparing Insulin Detemir With NPH Insulin in 310 Pregnant Women With Type 1 Diabetes
por: Mathiesen, Elisabeth R., et al.
Publicado: (2012)

Effects of Insulin Detemir and NPH Insulin on Body Weight and Appetite-Regulating Brain Regions in Human Type 1 Diabetes: A Randomized Controlled Trial
por: van Golen, Larissa W., et al.
Publicado: (2014)

Detemir as a once-daily basal insulin in type 2 diabetes
por: Nelson, Scott E
Publicado: (2011)

A Randomized Clinical Trial of Insulin Glargine and Aspart, Compared to NPH and Regular Insulin in Children with Type 1 Diabetes Mellitus
por: Rostami, Parastoo, et al.
Publicado: (2014)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
por: Jakobsen, Marie, et al.
Publicado: (2012)

Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery
por: Ahmad, Mushtaq, et al.
Publicado: (2015)

Comorbidites in NPH - local introspective - ‘Shunt them all’!
por: Haylock-Vize, Patricia Anne, et al.
Publicado: (2015)

Pioglitazone and cause-specific risk of mortality in patients with type 2 diabetes: extended analysis from a European multidatabase cohort study
por: Strongman, Helen, et al.
Publicado: (2018)

Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)
por: Edelman, Steven, et al.
Publicado: (2023)

Addition of insulin glargine or NPH insulin to metformin monotherapy in poorly controlled type 2 diabetic patients decreases IGF-I bioactivity similarly
por: Varewijck, A. J., et al.
Publicado: (2012)

Plasma ceramides independently predict all-cause mortality in men aged 85(+)
por: Strandberg, Timo E, et al.
Publicado: (2022)

The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range
por: Elhabashy, Safinaz Adel, et al.
Publicado: (2023)

Comparison of Insulin Glargine and Detemir Effects on Hormones of Appetite and Metabolic Control in Patients with Type 1 Diabetes: A Randomized Clinical Trial
por: Razzaghy-Azar, Maryam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_agld7sgm0n9pagjmvobicj3h3f